Selling, General, and Administrative Costs: Catalent, Inc. vs Rhythm Pharmaceuticals, Inc.

A Tale of Two Companies: Catalent, Inc. vs. Rhythm Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. Catalent, Inc. and Rhythm Pharmaceuticals, Inc. offer a fascinating study in contrasts when it comes to their Selling, General, and Administrative (SG&A) expenses over the past decade.

Catalent, a leader in drug development, has seen its SG&A expenses grow steadily, peaking at approximately $935 million in 2024, a 180% increase from 2014. This growth reflects its expanding operations and market reach. In contrast, Rhythm Pharmaceuticals, a biotech firm focused on rare genetic disorders, started with minimal SG&A expenses in 2014. By 2023, these costs surged to around $118 million, marking a staggering increase of over 9,600%. This dramatic rise underscores Rhythm's aggressive push into the market.

While Catalent's expenses show consistent growth, Rhythm's rapid escalation highlights its strategic investments in innovation and market penetration.